Annexon, Inc.
NASDAQ: ANNX. Canonical company identity and public leadership record.
US
- Alpha ID
- alpha:company:c1f8f562-952b-4849-bcc2-7de87224b266
- SEC CIK
- 0001528115
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 17, 2026
- Newest evidence
- May 3, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Douglas LoveSince Apr 27, 2026
- Chair
- Not published
- Independent
- 7 / 88 directors published
- Published claims
- 334 distinct sources
- Evidence records
- 140 pinned
- Source conflicts
- 0None open
Built from 4 distinct sources and 14 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CEO CHANGED
Douglas Love executive of Annexon, Inc., effective 2026-04-27.
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| President, Chief Executive Officer and Class III Director | Douglas Love | Apr 2026 | current | Source reportedE4 |
| EVP Chief Medical Officer | Jamie Dananberg | Apr 2026 | current | Source reportedE5 |
| EVP Chief Financial Officer | Jennifer Lew | Apr 2026 | current | Source reportedE7 |
| EVP Chief Business Officer | Michael Overdorf | Apr 2026 | current | Source reportedE8 |
| EVP Chief Scientific Officer | Rick Artis | Apr 2026 | current | Source reportedE10 |
| EVP Chief Innovation Officer | Ted Yednock | Apr 2026 | current | Source reportedE12 |
| President, Chief Executive Officer and Class III Director | Douglas E. Love, Esq. | Not captured | unknown | Source reportedE3 |
| EVP Chief Medical Officer | Jamie Dananberg, M.D. | Not captured | unknown | Source reportedE6 |
| EVP Chief Business Officer | Michael Overdorf, M.B.A. | Not captured | unknown | Source reportedE9 |
| EVP Chief Scientific Officer | Rick Artis, Ph.D. | Not captured | unknown | Source reportedE11 |
| EVP Chief Innovation Officer | Ted Yednock, Ph.D. | Not captured | unknown | Source reportedE13 |
Board of directors
Evidence8 directors published. 7 of 8 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Bettina M. Cockroft, M.D. | Independent | 2022 | None published | Source reportedE2 |
| Douglas E. Love | Not independent | 2014 | None published | Source reportedE2 |
| Jung E. Choi | Independent | 2020 | Compensation, chairCompensation · Chair | Source reportedE2 |
| Muneer A. Satter | Independent | 2014 | AuditAudit; Nominating and Governance · ChairNominating and Governance, chair | Source reportedE2 |
| Thomas G. Wiggans | Independent | 2017 | CompensationCompensation; Nominating and GovernanceNominating and Governance | Source reportedE2 |
| William (BJ) Jones, Jr. | Independent | 2025 | None published | Source reportedE2 |
| William D. Waddill | Independent | 2021 | Audit, chairAudit · Chair; Nominating and GovernanceNominating and Governance | Source reportedE2 |
| William H. Carson, M.D. | Independent | 2021 | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | William D. Waddill | William D. Waddill, Muneer A. Satter | Not described in the published record |
| Audit · Chair; Nominating and Governance | Not published | William D. Waddill | Not described in the published record |
| Audit; Nominating and Governance · Chair | Not published | Muneer A. Satter | Not described in the published record |
| Compensation | Jung E. Choi | Jung E. Choi, Thomas G. Wiggans | Not described in the published record |
| Compensation · Chair | Not published | Jung E. Choi | Not described in the published record |
| Compensation; Nominating and Governance | Not published | Thomas G. Wiggans | Not described in the published record |
| Nominating and Governance | Muneer A. Satter | Muneer A. Satter, Thomas G. Wiggans, William D. Waddill | Not described in the published record |
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Financials and market context
EvidenceGovernance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Douglas LovePresident, Chief Executive Officer and Class III Directorcompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:14
- Jamie DananbergEVP Chief Medical Officercompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:15
- Jennifer LewEVP Chief Financial Officercompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:17
- Michael OverdorfEVP Chief Business Officercompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:18
- Rick ArtisEVP Chief Scientific Officercompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:20
- Ted YednockEVP Chief Innovation Officercompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:22
- Douglas E. Love, Esq.President, Chief Executive Officer and Class III Directorcompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:13
- Jamie Dananberg, M.D.EVP Chief Medical Officercompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:16
- Michael Overdorf, M.B.A.EVP Chief Business Officercompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:19
- Rick Artis, Ph.D.EVP Chief Scientific Officercompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:21
- Ted Yednock, Ph.D.EVP Chief Innovation Officercompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:23
- Bettina M. Cockroft, M.D.Directorcompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:5
- Douglas E. LoveDirectorcompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:6
- Jung E. ChoiDirectorcompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:7
- Muneer A. SatterDirectorcompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:8
- Thomas G. WiggansDirectorcompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:9
- William (BJ) Jones, Jr.Directorcompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:10
- William D. WaddillDirectorcompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:11
- William H. Carson, M.D.Directorcompany:c1f8f562-952b-4849-bcc2-7de87224b266:leadership_role:12
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 14 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 17, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 23, 2025. Retrieved Apr 24, 2026. Cited by 8 Claims.
- E3ANNX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E4sec filing. Published Apr 27, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 27, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E6ANNX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E7sec filing. Published Apr 27, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E8sec filing. Published Apr 27, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E9ANNX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E10sec filing. Published Apr 27, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E11ANNX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E12sec filing. Published Apr 27, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E13ANNX executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E14board_seats. board seats. Cited by 10 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 17, 2026- Douglas Love executive of Annexon, Inc., effective 2026-04-27.
- Jamie Dananberg executive of Annexon, Inc., effective 2026-04-27.
- Jennifer Lew executive of Annexon, Inc., effective 2026-04-27.
- Michael Overdorf executive of Annexon, Inc., effective 2026-04-27.
- Rick Artis executive of Annexon, Inc., effective 2026-04-27.
- Ted Yednock executive of Annexon, Inc., effective 2026-04-27.
- William (BJ) Jones, Jr. seat on Annexon, Inc., effective 2025-01-01.
- Bettina M. Cockroft, M.D. seat on Annexon, Inc., effective 2022-01-01.
- William D. Waddill seat on Annexon, Inc., effective 2021-01-01.
- William H. Carson, M.D. seat on Annexon, Inc., effective 2021-01-01.
- Audit · Chair; Nominating and Governance committee of Annexon, Inc., effective 2021-01-01.
- William D. Waddill member of Audit · Chair; Nominating and Governance, effective 2021-01-01.
- Jung E. Choi seat on Annexon, Inc., effective 2020-01-01.
- Compensation · Chair committee of Annexon, Inc., effective 2020-01-01.
- Jung E. Choi member of Compensation · Chair, effective 2020-01-01.
- Thomas G. Wiggans seat on Annexon, Inc., effective 2017-01-01.
- Compensation; Nominating and Governance committee of Annexon, Inc., effective 2017-01-01.
- Thomas G. Wiggans member of Compensation; Nominating and Governance, effective 2017-01-01.
- Douglas E. Love seat on Annexon, Inc., effective 2014-01-01.
- Muneer A. Satter seat on Annexon, Inc., effective 2014-01-01.
- Audit; Nominating and Governance · Chair committee of Annexon, Inc., effective 2014-01-01.
- Muneer A. Satter member of Audit; Nominating and Governance · Chair, effective 2014-01-01.

